Recently, the results of the "Deloitte Technology Fast Program" were announced, and VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder") was awarded the title of "" by virtue of its comprehensive advantages in the founding team, technological innovation, industry ranking, financing and other aspects2023 China Rising Star"And".The rising star of China's medicine and health"Enterprise. On January 19, a team of experts from the Deloitte Selection Committee visited VectorBuilder, and Mr. Yu Yang, Deloitte China's Audit & Assurance Leader in South China Region, presented the award to VectorBuilder.
VectorBuilder and Deloitte team.
The Deloitte Technology Fast Program is "committed to identifying and recognizing fast-growing, innovative and resilient technology companies, and has been held in dozens of countries and regions around the world for 29 years, and has been held in China for 19 consecutive years."A benchmark for high-growth companies around the worldMany industry leaders have emerged in the list over the years, such as: Tencent, Alibaba, JD.com, ByteDance, SMIC, WuXi AppTec, Mindray Healthcare, DJI, Apple, Microsoft, Amazon, Google, and TeslaBecause companies are usually in the early stages when they are selected for the list, the list is also known as the "cradle of great technology companies".
"Rising Star" is a key sub-program of the Deloitte Technology Fast Program, which aims to identify and recognize outstanding companies that are leading in their niches and have great growth potentialThere are 75 "China Rising Star" companies, including 8 unicorn companiesA total of 50 enterprises with outstanding comprehensive strength were selected as "Rising Stars of China's Medicine and Health".This year, Deloitte has launched a key selection program in line with the latest industry trends, and the winners include advanced enterprises in various segments of the pharmaceutical and health care sectors, demonstrating diversified innovation achievements in the life sciences and healthcare fields in an all-round way.
VectorBuilder "China Rising Star" trophy.
VectorBuilder "China Pharmaceutical and Health Rising Star" trophy.
Under the leadership of Chief Scientist Dr. Lan Tian and the global and professional core team, VectorBuilder has opened the era of commercialization of customized gene vectors with the world's original online gene vector intelligent design and ordering platform "Vectorbuilder". At the same time, VectorBuilder has developed into the downstream market with a funnel-style and full-chain development layout, providing gene delivery CRO and gene vector CDMO services, becoming one of the few companies in the industry that can provide full-chain services from scientific research to clinical gene delivery.
At present, VectorBuilder has served more than 4,500 scientific research institutions and pharmaceutical companies in more than 90 countries and regions around the world, with a customer coverage rate of 90% among the top 100 universities in the 2023 QS (QS World University Rankings), and more than 1,000 global literature citations for its product achievements, including nearly 400 articles published in the world's top journals such as Science, Nature, and Cell. CRO and CDMO projects are located in North America, Europe, Japan and other countries and regions. VectorBuilder has received a total of more than 500 million yuan in financing, becoming the first biotechnology unicorn company in Guangzhou with a valuation of 7 billion yuan, and has submitted for listing on the Science and Technology Innovation Board in 2023 and has been accepted.
In the future, VectorBuilder will continue to strengthen its innovation level and technical strength, continuously improve the quality of gene delivery products and services, and further explore the global market through the influence and popularity of "Tomorrow's Star", so as to better empower basic scientific research and clinical applications.